Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Lung Neoplasms 44Carcinoma, Hepatocellular 42Small Cell Lung Carcinoma 28Breast Neoplasms 18Cholangiocarcinoma 17Urinary Bladder Neoplasms 16Biliary Tract Neoplasms 15Liver Neoplasms 13Neoplasms 12Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Pancreatic Neoplasms 11Ovarian Neoplasms 9Carcinoma 9Squamous Cell Carcinoma of Head and Neck 8Endometrial Neoplasms 7Colorectal Neoplasms 7Stomach Neoplasms 6Carcinoma, Transitional Cell 6Melanoma 5Gallbladder Neoplasms 5Esophageal Neoplasms 5Carcinoma, Renal Cell 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Prostatic Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Neoplasms by Site 4Mesothelioma 4

Interventions

Magnetic Resonance Spectroscopy 18pembrolizumab 16Specimen Handling 15Cisplatin 14Carboplatin 9Platinum 8Cetuximab 81,2-diaminocyclohexaneplatinum II citrate 8Radiotherapy, Intensity-Modulated 7Radiation 7Paclitaxel 7Biopsy 7Taxes 6Radiotherapy 6cemiplimab 4X-Rays 4Standard of Care 4Nivolumab 4Drug Therapy 4(225)Ac-DOTA-c(RGDyK) 4durvalumab 3Ultrasonography 3Surgical Procedures, Operative 3Sentinel Lymph Node Biopsy 3Observation 3Immunoglobulin G 3Disulfides 3ipatasertib 2Watchful Waiting 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Mouth Neoplasms × durvalumab × 1 year × Clear all
NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
39 enrolled 8 charts
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03529422 2025-07-20

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
18 enrolled 10 charts
Head & Neck

Lymphoid Interstitial Pneumonia, Laryngeal Diseases, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡